These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19697277)

  • 1. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
    Bredenoord AJ
    IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.
    Brändén L; Fredriksson A; Harring E; Jensen J; Lehmann A
    Eur J Pharmacol; 2010 May; 634(1-3):138-41. PubMed ID: 20176012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
    Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
    Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
    Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
    Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.
    Boeckxstaens GE; Beaumont H; Mertens V; Denison H; Ruth M; Adler J; Silberg DG; Sifrim D
    Gastroenterology; 2010 Aug; 139(2):409-17. PubMed ID: 20451523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
    J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?
    Falk GW
    Gastroenterology; 2010 Aug; 139(2):377-9. PubMed ID: 20600061
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects.
    Boeckxstaens GE; Rydholm H; Lei A; Adler J; Ruth M
    Aliment Pharmacol Ther; 2010 Jun; 31(11):1208-17. PubMed ID: 20222915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
    Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
    Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease.
    Lehmann A; Jensen JM; Boeckxstaens GE
    Adv Pharmacol; 2010; 58():287-313. PubMed ID: 20655487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel treatments of GERD: focus on the lower esophageal sphincter.
    Lehmann A
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABAB receptors as drug targets to treat gastroesophageal reflux disease.
    Lehmann A
    Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.
    Miner PB; Silberg DG; Ruth M; Miller F; Pandolfino J
    BMC Gastroenterol; 2014 Nov; 14():188. PubMed ID: 25407279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
    Alstermark C; Amin K; Dinn SR; Elebring T; Fjellström O; Fitzpatrick K; Geiss WB; Gottfries J; Guzzo PR; Harding JP; Holmén A; Kothare M; Lehmann A; Mattsson JP; Nilsson K; Sundén G; Swanson M; von Unge S; Woo AM; Wyle MJ; Zheng X
    J Med Chem; 2008 Jul; 51(14):4315-20. PubMed ID: 18578471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of gastroesophageal reflux disease (GERD)].
    Storr M
    Med Monatsschr Pharm; 2011 Dec; 34(12):446-54; quiz 455-6. PubMed ID: 22233024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reflux inhibitors: a new approach for GERD?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
    Tack J
    Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of gastro-esophageal reflux disease: the new kids to block.
    Blondeau K
    Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.